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Abstract
Background: Approximately 10–15 % of gastrointestinal stromal tumors (GISTs) lack gain of function mutations in
the KIT and platelet-derived growth factor receptor alpha (PDGFRA) genes. An alternate mechanism of oncogenesis
through loss of function of the succinate-dehydrogenase (SDH) enzyme complex has been identified for a subset of
these “wild type” GISTs.
Methods: Paired tumor and normal DNA from an SDH-intact wild-type GIST case was subjected to whole exome
sequencing to identify the pathogenic mechanism(s) in this tumor. Selected findings were further investigated in
panels of GIST tumors through Sanger DNA sequencing, quantitative real-time PCR, and immunohistochemical
approaches.
Results: A hemizygous frameshift mutation (p.His2261Leufs*4), in the neurofibromin 1 (NF1) gene was identified in the
patient’s GIST; however, no germline NF1 mutation was found. A somatic frameshift mutation (p.Lys54Argfs*31) in the
MYC associated factor X (MAX) gene was also identified. Immunohistochemical analysis for MAX on a large panel of
GISTs identified loss of MAX expression in the MAX-mutated GIST and in a subset of mainly KIT-mutated tumors.
Conclusion: This study suggests that inactivating NF1 mutations outside the context of neurofibromatosis may be the
oncogenic mechanism for a subset of sporadic GIST. In addition, loss of function mutation of the MAX gene was
identified for the first time in GIST, and a broader role for MAX in GIST progression was suggested.
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Background
Gastrointestinal stromal tumor (GIST) is a mesenchymal
neoplasm that originates throughout the GI tract, pri-
marily in the stomach (>50 %) and small intestine
(~30 %) [1]. GIST generally presents in older adults,
while ~2 % of cases are children [2, 3]. Originally
thought to be of smooth muscle origin, immunohisto-
chemical and ultrastructural studies suggest that GIST
is related to spindle-shaped cells of the GI tract
known as the interstitial cells of Cajal (ICC) [4, 5].
ICC and the majority (95 %) of GIST express the type
III receptor tyrosine kinase KIT (CD117), and variably
exhibit myoid or neural features. The majority of
GISTs exhibit gain of function mutations in KIT or in
the related receptor PDGFRA [6, 7]. A subset (~10–15 %)
of GISTs in adults lack mutations in the KIT and PDGFRA
genes, as do almost all pediatric cases [8, 9]. The
commonly used label of “wild type” (WT) GIST belies
the epidemiological, clinico-pathological and molecu-
lar heterogeneity that define these tumors. WT GIST
occurs in the context of several multitumor syndromes,
including the inherited Carney-Stratakis Syndrome (CSS)
and the non-familial Carney triad (CT). Manifestations of
CSS and CT include gastric GIST and paraganglioma
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(PGL), a neural crest-derived tumor, while the spectrum
of CT neoplasms includes pulmonary chondroma and
several other neoplasms [10, 11]. CSS results from loss of
function mutations in subunit genes of the succinate-
dehydrogenase (SDH) enzyme complex, SDHB, SDHC,
and SDHD [12]. Inactivation of the SDHA gene subunit
has recently been implicated as a causative factor in a sub-
set of apparently sporadic adult WT GIST (reviewed in
[13]). GISTs from CT patients do not manifest SDHX mu-
tations; however, these tumors are also SDH-deficient, and
the molecular underpinning of CT GIST has been attrib-
uted to epigenetic silencing of the SDHC gene [14].
Pediatric GIST patients share hallmarks of CT-associated
GIST, namely early-onset, multi-focal, gastric disease with a
predilection towards females [8], and pediatric GIST cases
have also been associated with SDHC epimutation [15].
Thus the identification of SDH-deficient GIST, also referred
to as “type 2”, helps distinguish between KIT/PDGFRAmu-
tant, or type I GIST, and a majority of wild type GIST.
SDH-intact WT GISTs with alternate oncogenic events
have been described. Mutations in the serine-threonine
kinase gene BRAF have recently been identified in ap-
proximately 5–15 % of sporadic wild type GIST [16].
These tumors are generally KIT-positive with spindle cell
or mixed morphology, and are found primarily in the
small intestine in adult cases. Approximately 1–2 % of
GISTs occur in the context of neurofibromatosis type I
(NF1) [1], an autosomal dominant disorder with skin and
ophthalmologic manifestations that predisposes to a var-
iety of benign and malignant tumors. GIST in NF1 indi-
viduals also present typically in the small bowel with
spindle-cell morphology, are found in men and women at
a younger median age than KIT/PDGFRA mutant GIST,
and are often multifocal [17, 18]. Neurofibromatosis is
due to germline mutations in neurofibromin 1, a RAS-
GAP protein and negative regulator for RAS signaling,
and germline NF1 mutations accompanied by somatic
events have been identified in NF1 GIST cases [19].
In this report we describe whole exome sequencing
(WES) of a particularly complex, SDH-intact wild type
GIST case. The WES analysis identified for the first time
the somatic inactivation of NF1 in a GIST outside the
context of NF1 syndrome. A novel somatic loss of func-
tion mutation in the MYC-associated factor X (MAX)
gene was also identified. Immunohistochemical studies
of a panel of GISTs identified deficiencies in MAX ex-
pression in a number of tumors. Implications for these
and other identified mutations are discussed.
Methods
Preparation of genomic DNA and total RNA
De-identified tumor samples and normal blood were
obtained following written informed consent from the
Fox Chase Cancer Center Biosample Repository. The
protocol was approved by the Fox Chase Cancer Center
Institutional Review Board (#03-848). The isolation and
characterization of genomic DNA and total RNA
from frozen tumor specimens embedded in optimum-
temperature cutting medium has been described [20].
Whole exome sequencing data analysis
Exome-enriched genomic libraries (TruSeq, Illumina,
San Diaego CA) from normal and tumor DNA were
subjected to paired-end 100 bp sequencing on the
Illumina HiSeq 2000 instrument. Reads were mapped to
the 1000Genome Project reference human genome
(Hg19 corresponding v37) using the BWA aligner [21]
and mapped reads were sorted, merged, and de-
duplicated (Picard), yielding an average of 51.6 million
unique mapped reads per sample. GATK realignment
was used to realign reads locally in areas surrounding in-
sertions and deletions (indels) [22, 23]. Variant calling
and filtering was performed using GATK UnifiedGenoty-
per [22, 23] and single nucleotide variants (SNVs) anno-
tated with modified ANNOVAR [24]. This pipeline
yielded an average SNV rate of ~ 0.34 % per sample.
The downstream analysis of SNVs and indels was done
by custom Perl scripts. Non-synonymous, potentially
deleterious coding region variants, splice-site mutations,
and indels that were predicted to be present in the
tumor only, were visually confirmed on the Integrative
Genomics Viewer (IGV) [25], and confirmed by exon-
based Sanger sequencing. Confirmed somatic indels, and
deleterious missense mutations predicted by the SIFT al-
gorithm [26] and confirmed by a consensus approach
[27] are listed in Table 1. Mutation nomenclature con-
forms to the recommendations of the Human Genome
Variation Society [28].
Sanger sequencing
Primers for amplification and sequencing of KIT (exons
9, 11, 13, 17), PDGFRA (exons 12, 14, 18), and BRAF
(exons 11,15) have been described [29], as have primers
for SDHA [30] and SDHB-D [31]. Primer sequences for
confirmation of mutations listed in Table 1 and MAX
genomic sequencing are shown in Additional file 1:
Table S1. Relevant exons were PCR-amplified from gen-
omic DNA and subjected to Sanger sequencing (Beckman
Coulter Genomics).
Immunohistochemical analysis
GIST tissue microarrays (TMAs) were constructed in
conjunction with the FCCC Biosample Repository.
H&E-stained sections from paraffin-embedded tissue
blocks were evaluated by a pathologist for tumor content
and cellularity, and two cores from each block were se-
lected for the TMA. Each TMA consists of ~ 30 GIST
specimens along with normal tissue sections. IHC for
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MAX was performed with the SC-197 antibody (Santa
Cruz Biotechnology, Dallas TX) at a 1:400 dilution
with antigen retrieval. Aperio Digital Pathology (Leica
Biosystems, Buffalo Grove, IL) was used to capture
and quantify MAX-stained TMAs using the nuclear
algorithm. MAX-deficient cases were confirmed on
whole-tissue sections, as were a subset of MAX-positive
cases. IHC for KIT was performed as described [32].
Gene expression analysis
Random-primed cDNA was prepared from 2 μg total
RNA using the High Capacity cDNA Reverse Transcription
KIT (Life Technologies). RNA expression was measured by
real-time PCR (qRT-PCR) on an ABI PRISM 7900 HT Se-
quence Detection System using fluorescein phosphorami-
dite (FAM) primer/probe sets (Applied Biosystems).
RNA expression data for MAX were normalized using
hypoxanthine guanine phosphoribosyl transferase 1
(HPRT1) and glucuronidase beta (GUSB). Taqmen sets
used were Hs99999909_m1 (HPRT1), Hs99999908_m1
(GUSB), and Hs00811069_g1 (MAX).
Results
The patient first presented at the age of 54 with a high-
risk GIST of the small bowel. Resections of several local
and distant recurrences were documented over several
years, and the patient was treated with imatinib, suniti-
nib, and several additional targeted agents. A locally re-
current 1.5 cm small bowel tumor was resected, and a
small portion of flash-frozen tumor and a whole blood
sample were provided following informed consent.
Formalin-fixed paraffin embedded (FFPE) tissue from an
earlier small bowel resection was also available. Histo-
logic evaluation of these specimens indicated a high-
cellularity spindle-cell tumor with a high mitotic index
(5-10/50 HPF) and no necrosis.
Sanger sequencing of DNA from the flash-frozen
tumor indicated that no mutations were present in the
“hotspot” exons of KIT, PDGFRA, or BRAF. Exon-based
sequencing of the SDH complex subunit genes SDHA-D
identified no SDHX mutations, and the tumor was
immunohistochemically positive for SDHB expression
[20]. These analyses suggested that the case belonged to
the small subset of SDH-intact and KIT, PDGFA, BRAF
wild-type GIST, for which no clear molecular pathogenic
mechanism has been established. DNA from this GIST
and from the patient’s blood was therefore subjected
to whole-exome sequencing (WES) (see Materials and
Methods).
WES analysis identified a two-base insertion
(c.6781_6782insTT; p.His2240Leufs*4) in exon 44 in
the Neurofibromatosis type I gene (NF1) that was con-
firmed by Sanger sequencing (Fig. 1a and Table 1). The
mutation is not seen in the patient’s germline DNA, and
the wild type allele is not represented in the tumor in ei-
ther the WES or Sanger analysis. A previously reported
single-nucleotide polymorphism (SNP) array analysis of
this GIST (case 26 [29]) identified copy-number loss of
the region encompassing the NF1 gene locus, suggesting
somatic NF1 gene inactivation through the frameshift mu-
tation combined with loss of the wild type gene. This par-
ticular NF1 mutation was not found in the COSMIC [33],
ClinVar [34] or Leiden Open Variation databases [35]. To
our knowledge this is the first reported example of GIST
with an inactivating NF1 mutation outside the context of
the NF1 syndrome. This sporadic GIST does share certain
characteristics with GISTs from NF1 patients, such as
small bowel origin, spindled-cell morphology, and immu-
nopositivity for KIT and SDHB [36]. It is reasonable to
suggest that somatic NF1 gene inactivation may be a
causative factor in formation of the patient’s disease.
WES analysis also identified a truncating frameshift
mutation (c.160delC; p.Gln54Lysfs*10) in exon 3 of the
MYC-associated factor (MAX) gene in the tumor DNA
(Fig. 1b and Table 1). This mutation was found in 91 %
of the WES reads. MAX is a basic helix-loop-helix (H-L-H)
leucine zipper (LZ) transcription factor and a key member
of the MYC/MAX/MXD network [37]. This truncating
Table 1 Confirmed somatic mutations
Gene symbol UniProt accessiona Genomic coordinateb Exon Mutation (cDNA) Mutation (protein) Allele frequency Consensus effectc
NF1 P21359 chr17:29665119 44 c.6781_6782insTT p.His2240Leufs*4 100 n/ad
MAX P61244 chr14:65560437 3 c.160delC p.Gln54Lysfs*10 91 n/ad
RTN4 Q9NQC3 chr2:55200745 8 c.3486_3490delAGAT p.Asp1163Ilefs2 36 n/ad
CCDC66 A2RUB6 chr3:56650054 13 c.1818_1819insCCT p.Ser606_Lys607insPro 29 n/ad
MVD P53602 chr16:88725087 2 c.112T>A p.S38T 58 Deleterious
MAFA Q8NHW3 chr8:144511807 1 c.770A>T p.Q257L 56 Likely deleterious
RNF123 Q5XPI4 chr3:49751544 31 c.2947T>G p.Y983D 52 Likely deleterious
SPIN4 Q56A73 chrX:62570610 1 c.89G>T p.R30L 47 Likely deleterious
SELP P16109 chr1:169565261 12 c.2003G>T p.C668F 49 Likely deleterious
ahttp://www.uniprot.org; bHg19; chttp://www.mypeg.info; dNot applicable
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mutation is predicted to disrupt domains responsible for
MAX homo-dimerization and hetero-dimerization [38]. In-
activating MAX mutations have recently been reported in
inherited and sporadic PGL and pheochromocytomas (PCC)
[39, 40], and in small cell lung cancer (SCLC) specimens
[41]. No mutations in MAX have been reported in GIST,
and we did not find additional MAX mutations in a sample
set of 16 wild-type tumors from 11 patients. However, these
WT GIST are all SDH-negative tumors, and exhibit
other characteristics (e.g. gastric location, epithelioid
cell morphology, lack of genome complexity) [20] that
are not found in our index case. An earlier report
documented a significant reduction in MAX expres-
sion in association with copy-number loss surround-
ing the MAX gene locus in a set of kinase-mutant
GISTs [42]. We hypothesized that reduction or loss of
MAX expression may be associated with mutant
GIST. To test this hypothesis, immunohistochemistry
from MAX was carried out on a series of ~80 GIST
specimens contained on 3 GIST tissue microarrays
(TMAs). The antibody was first tested against human
seminal vesicle tissue, which exhibited strong nuclear
staining (Fig. 2, panel a). Staining of the GIST from
the patient’s earlier resection confirmed complete ab-
sence of MAX and strong plasma membrane staining
for KIT in the tumor (Fig. 2, panels b and c respect-
ively). IHC analysis of the 3 TMAs identified a wide
range of MAX staining in GIST sections, ranging
from strong, widely distributed nuclear staining to
complete or near-complete absence of staining. Im-
ages were captured and quantified (Materials and
Methods). Nuclear staining intensity (0–3) and distri-
bution (0–100) were combined to generate nuclear
H-Scores, with a potential range of 0–300. The mean
nuclear H-score across the GIST samples on the
TMA was 99.7 (0–252). Visual re-examination of the
stained spots suggested H-scores <20 as a reasonable
cutoff below which very little positive nuclear staining
was seen. Whole tissue sections from a number of
these tumors were re-stained with MAX, and the
Fig. 1 a WES (top) and Sanger (bottom) sequencing showing the two-base (TT) insertion in NF1. A subset of reads visualized on the Integrative
Genomics Viewer (IGV) shows the insertion represented by the purple bar in 100 % of the tumor reads, as confirmed by the chromatogram
below. b Top and bottom panels show the single-base (c) deletion in the MAX gene in a majority (~90 %) of reads, again confirmed by the
chromatogram below. Red arrow indicates direction of transcription for MAX
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TMA results confirmed in 10 of these cases (Table 2
and Fig. 2). Several GISTs that exhibited strong or
intermediate nuclear MAX staining are shown in
Fig. 2 (panels d-f, with H-scores of 210, 192, and
84.8, respectively). In Fig. 2, panels g-p correspond to
Cases 1–10 in Table 2. These images generally cor-
roborate the low nuclear MAX H-scores from the
TMA, although some tissues show isolated nuclear
staining (e.g. panel h).
Table 2 lists the clinico-pathological characteristics of
the 10 MAX-deficient cases. Nine cases harbor KIT exon
11 mutations, while one patient’s tumor exhibited a mu-
tation in exon 18 of PDGFRA. The cases are mainly
males (7 of 9 available), with an average age of presenta-
tion of 56.9 years. Most were of gastric origin, and nine
were high- or intermediate-risk GIST. None of these pa-
rameters varied significantly however when compared to
the rest of the sample set (Additional file 2: Table S2).
Exon-based Sanger sequencing of eight of these cases
did not identify any mutations in MAX.
Table 1 lists several other confirmed somatic muta-
tions in our index case: two indels and five missense
mutations that were predicted to affect protein structure
or function. The variant calls represent ~30–60 % of the
total reads at these positions, and exon-based Sanger se-
quencing confirmed that these mutations were at most
heterozygous in the tumors. A frameshift deletion in
reticulon 4 (RTN4) was identified, along with an in-
frame insertion in the coiled-coiled domain-containing
protein CCDC66. Missense mutations were identified in 5
genes: the gene encoding the enzyme mevalonate decarb-
oxylase (MVD) that catalyzes an early step in cholesterol
synthesis; MAFA (musculoaponeurotic fibrosarcoma onco-
gene family, protein A), a transcription factor that controls
insulin gene expression in the pancreas; the ring-finger
protein gene RNF123, which acts as a ubiquitin ligase
Fig. 2 Immunohistochemistry for MAX and KIT. a Control staining of nuclear MAX in seminal vesicles. b Negative staining for MAX in index case.
c Strong plasma membrane straining for KIT/CD117 in index case. d-f Strong nuclear staining for MAX in MAX-positive GISTs. g-p Mainly negative
nuclear staining for MAX in GIST cases 1–10. Red bar: 10 μM
Table 2 Description of MAX-negative cases
Case H-scorea Age/Sex Genotype Riskb Site
1 0.0 71/M PDGRA exon 18 H Gastric
2 3.2 48/F KIT exon 11 H Gastric
3 5.0 83/M KIT exon 11 I Gastric
4 5.9 39/M KIT exon 11 L Gastric
5 7.4 35/M KIT exon 11 H Other
6 10.9 n/ac KIT exon 11 H n/ac
7 13.6 46/M KIT exon 11 I Gastric
8 13.9 68/F KIT exon 11, 17 H Small bowel
9 14.2 72/M KIT exon 11 I Gastric
10 17.6 50/M KIT exon 11 I Gastric
aH-score: nuclear staining intensity x percentage; bGIST prognosis based on
tumor site, size, mitotic index. H= high, I = intermediate, L = low;
cNot available
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towards the cyclin-dependent kinase inhibitor KIP1;
a member of the spindlin family of chromatin readers
(SPIN4); and the SELP (selectin P) gene, encoding
a calcium-dependent receptor that mediates the inter-
action of activated endothelial cells or platelets with
leukocytes.
Discussion
This study is the first report of somatic inactivation of
the NF1 gene in a sporadic SDH-intact GIST lacking
gain of function mutations in KIT, PDGFR, and BRAF.
Although tissue from the primary tumor from this pa-
tient was not available for analysis, it is reasonable to
suggest that somatic inactivation of NF1 may have been
an early causative event in this case. NF1 patients are
~45X more likely to develop GIST than the general
population [17], and it has been estimated that 1–2 % of
GIST arise in patients with NF1 [1]. GISTs in NF1 pa-
tients commonly lack activating mutations in the KIT
and PDGFRA receptors [17, 18, 43], and may owe their
incidence to germline NF1 mutation coupled with som-
atic second hits, as has been demonstrated in some cases
[19, 44, 45]. It is perhaps not surprising to find NF1 gene
inactivation in a sporadic wild-type GIST, as NF1
somatic mutations have been identified in a number of
non-NF1-associated tumor types (reviewed in [44]).
Moreover, while PCCs are known to occur in the con-
text of NF1 [46], NF1 somatic mutations were also iden-
tified in a high percentage (21/61) of sporadic PCC
selected for specific gene expression patterns or low
levels of NF1 gene expression [47]. The finding of NF1
gene inactivation in sporadic GIST has diagnostic impli-
cations, as the molecular identification of mutations in
the large and complex NF1 gene is a challenging task. A
comprehensive approach combining NF1 transcript and
genomic sequencing with multiplex ligation dependent
probe amplification and other techniques for detection
of gene duplications and deletions has been used to de-
tect mutations in up to 95% of NF1 cases [48]. Immu-
nohistochemical approaches using available anti-NF1
antibodies have been largely unsuccessful in identifying
NF1-mutated PCC with a high degree of sensitivity or
specificity [47, 49]. Recently, WES approaches have been
used to identify the germline and somatic NF1 events in
various tumors from an NF1 patient [50]. Whether
NF1 inactivation is a common event in sporadic,
SDH-intact wild type GIST is an open question. In a
recent transcriptome-sequencing study [51], no NF1
mutations were identified in two SDH intact wild-type
GIST, although it has been shown that only a portion of
exonic variants are typically captured by RNA-seq ap-
proaches [52]. Interestingly, next-generation sequencing
of eight SDH-negative GIST cases using a targeted cancer-
associated gene capture library identified a low-frequency
(8 %) frameshift NF1 mutation in a GIST that also har-
bored an activating KRAS gene mutation (G12V) [53].
The identification of a loss of function mutation in the
MAX gene is a novel finding in GIST. As a hetero-
dimeric partner for MYC, MAX was originally thought
to be required for oncogenic pathways initiated by MYC
over-expression [54]. However, in MAX-deficient rat
PC12 PCC cell lines it has been shown that MAX is
dispensable for MYC transcriptional regulation [55].
Intriguingly, MAX inactivation has recently been im-
plicated in both inherited and sporadic PCC and PGL
cases [39, 40]. Mutation of MAX is a relatively rare
event in these tumors, accounting for 1.12 % of her-
editary PCC/PGL lacking mutations in other suscepti-
bility genes and 1.65 % of sporadic cases. In the
familial PCC cases preferential transmission of the
disease from the paternal allele was observed, along
with a tendency towards aggressive behavior. A recent
report also describes MAX inactivation in 6 % of pri-
mary SCLC specimens [41]. The authors suggest that
SCLC, like PCC, may arise from neuroendocrine cells
or differentiate towards neural features, which may
explain the shared mechanism of MAX-associated
oncogenesis. Similarly, sub-populations of GISTs may
also variably exhibit neural properties or markers, and
in a recent report a set of SDH-intact WT GIST was
shown to exhibit high relative expression of neural
markers, along with expression of members of the
insulin-like growth family network [56]. In SCLC, in-
activating MAX mutations were found to be mutually
exclusive with amplifications of hetero-dimeric part-
ners MYC, MYCL1, and MYCN, and mutations in
BRG1, which encodes an ATPase of the SWI/SNF
chromatin -remodeling complex that regulates expres-
sion of MYC, MYC target genes, as well as MAX. In
GIST, the contributions of the MYC/MAX/MXD net-
work to pathogenesis have not been extensively de-
scribed. There have been descriptions of amplification
of the MYC gene locus on chromosome 8q [57, 58],
and reduced mRNA expression of the MAX gene as-
sociated with copy number loss of chromosome14q
[42]. These secondary chromosome aberrations are
common in KIT/PDGFRA-mutated GIST [59]. In this
report we used immunohistochemical approaches to
identify reduced/absent MAX nuclear staining in 10/78
(~13 %) of GIST cases analyzed, in addition to the index
case. We found no additional MAX mutations in these tu-
mors, and MAX RNA expression was only marginally and
not significantly reduced (1.3-fold, P = 0.47) compared to
the remaining MAX-positive cases. Further investigations
into the mechanism(s) of MAX dysregulation and its con-
tribution to pathogenesis in GIST are warranted.
In addition to inactivating NF1 and MAX mutations
found in our index case, we also identified a heterozygous
Belinsky et al. BMC Cancer  (2015) 15:887 Page 6 of 9
4-base deletion in RTN4 and an in-frame insertion in
CCD66, as well as potentially pathogenic substitutions in
the MVD, MAFA, RNF123, SPIN4, and SELP genes. Al-
though to our knowledge these genes have not been stud-
ied in GIST, a recent systems biological approach to
identifying key transcriptional regulators in GIST and leio-
myosarcoma identified nine differentially expressed genes,
including the MYC gene, the MAF gene which encodes
another basic leucine zipper (bZIP)-containing transcrip-
tion factor closely related to MAFA, and another coiled-
coil domain containing transcription factor gene, CCDC6
[60]. The MAF proteins are members of the AP1 family:
the large MAF proteins contain transactivation domains
and are considered onco-proteins by virtue of their ability
to transform primary cells and induce tumors in various
animal models (reviewed in [61]). Interestingly, the Q257L
substitution we identified is located in the MAFA bZIP
domain, very close to the predicted DNA-binding domain
that has been shown to be required for MAFA transform-
ation activity in avian fibroblasts [62]. The substitution we
identified may affect the specificity or avidity of MAFA
binding to its target sequences.
Conclusions
In conclusion, next-generation sequencing of an SDH-
intact, KIT, PDGFR, BRAF wild type GIST identified for
the first time somatic loss of function mutations in two
tumor-suppressor genes, NF1 and MAX. Somatic inacti-
vation of neurofibromin should be explored as a poten-
tial oncogenic mechanism in this subset of GIST. The
identification of MAX inactivation provides another etio-
logical link between GIST and PGL/PCC, in addition to
mutations of the NF1 gene and mutations in the subunit
genes of the SDH complex that have been identified in
these tumors.
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